September 10, 2024
Health Canada Approves AbbVie’s CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age
September 9, 2024
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs
September 4, 2024
AbbVie’s VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for the Treatment of Schizophrenia
No current content.